[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-gastrointestinal-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-gastrointestinal-dysfunction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644856","anti-bloating-patch-for-postoperative-gastric-distension-after-cardiac-surgery-100644856",false,"NCT07677423","Anti-Bloating Patch for Postoperative Gastric Distension After Cardiac Surgery","Efficacy of an Anti-Bloating Patch for Postoperative Gastric Distension After Cardiac Surgery: A Randomized Controlled Trial Using Quantitative Gastric Bubble Imaging Analysis","ABP-CS","Inclusion Criteria:\n\n* Age ≥18 years\n* Undergoing elective cardiac surgery\n* Postoperative chest radiographs available for gastric bubble area assessment\n* Able to provide written informed consent or have consent provided by a legally authorized representative\n* Expected postoperative intensive care unit admission\n\nExclusion Criteria:\n\n* Previous major gastrointestinal surgery affecting gastric anatomy or motility\n* Known gastrointestinal obstruction, perforation, or severe gastrointestinal disease\n* Severe hepatic or renal dysfunction judged unsuitable by the investigators\n* Known allergy or hypersensitivity to components of the anti-bloating patch\n* Participation in another interventional clinical trial within the previous 30 days\n* Pregnancy or lactation\n* Inability to complete study assessments or follow study procedures","ALL","18 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Postoperative gastric distension is a common gastrointestinal complication after cardiac surgery and may delay recovery, prolong intensive care unit (ICU) stay, and reduce patient comfort. Anti-bloating patches are widely used in clinical practice to promote gastrointestinal function recovery; however, high-quality evidence regarding their effectiveness in cardiac surgical patients remains limited.\n\nThis randomized controlled trial aims to evaluate the efficacy and safety of an anti-bloating patch in reducing postoperative gastric distension after cardiac surgery. Adult patients undergoing cardiac surgery will be randomly assigned to receive either standard perioperative care alone or standard perioperative care plus anti-bloating patch therapy. Gastric bubble area will be quantitatively measured using chest radiographs and image analysis software.\n\nThe primary outcome is the change in gastric bubble area on postoperative day 1 compared with baseline. Secondary outcomes include gastric bubble area on postoperative day 1, percentage change in gastric bubble area, abdominal distension score, time to first flatus, time to first bowel movement, gastric drainage volume, time to oral feeding, ICU length of stay, postoperative hospital length of stay, and patch-related adverse events.\n\nThe results of this study may provide evidence for the use of anti-bloating patches as an adjunctive intervention to enhance postoperative gastrointestinal recovery in patients undergoing cardiac surgery.",[28,29,30],"Postoperative Gastric Distension","Postoperative Gastrointestinal Dysfunction","Cardiac Surgery",[32,28,33,30,34],"Anti-Bloating Patch","Gastric Bubble Area","Gastrointestinal Dysfunction","NOT_YET_RECRUITING","2026-06-27",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2027-07-01",{"name":45,"class":46},"Southeast University, China","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100605900","effect-of-tap-block-on-gi-function-after-sleeve-gastrectomy-using-pro-digi-scale-and-perlas-score-100605900","NCT07168538","Effect of TAP Block on GI Function After Sleeve Gastrectomy Using PRO-diGI Scale and Perlas Score","Effect of Transversus Abdominis Plane (TAP) Block on Postoperative Gastrointestinal Function After Laparoscopic Sleeve Gastrectomy: Evaluation Using the PRO-diGI Scale and Perlas Score (Prospective Clinical Study)","TAP","Inclusion Criteria:\n\n* Adult patients aged 18-65 years\n* Scheduled for primary laparoscopic sleeve gastrectomy (LSG)\n* Body Mass Index (BMI) ≥ 35 kg\u002Fm²\n* ASA Physical Status II-III\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Previous major abdominal surgery\n* Known allergy to local anesthetics\n* Severe hepatic or renal dysfunction\n* Pregnancy or breastfeeding\n* Conversion to open surgery during the procedure\n* Patients refusing TAP block or general anesthesia","65 Years",{"count":58,"type":22},60,"OBSERVATIONAL","This prospective clinical study aims to evaluate the effect of Transversus Abdominis Plane (TAP) block on postoperative gastrointestinal function in patients undergoing laparoscopic sleeve gastrectomy. Gastrointestinal recovery plays a crucial role in patient outcomes after bariatric surgery, and regional anesthesia techniques such as TAP block have been suggested to reduce postoperative pain and opioid consumption, which may influence gut motility.\n\nIn this study, postoperative gastrointestinal function will be assessed using the validated Patient-Reported Outcome for Dysfunctional Gastrointestinal Motility (PRO-diGI) scale. Additionally, gastric ultrasound will be performed to calculate the Perlas score as an objective marker of gastric emptying and residual volume. These assessments will allow a comprehensive evaluation of both subjective and objective gastrointestinal recovery parameters.\n\nThe study will include adult patients scheduled for elective laparoscopic sleeve gastrectomy at Elazığ Fethi Sekin City Hospital. Participants will receive standard general anesthesia with or without ultrasound-guided TAP block, and their postoperative recovery will be monitored. Primary outcomes include PRO-diGI scores at defined postoperative intervals, while secondary outcomes include Perlas scores obtained via gastric ultrasonography.\n\nThe findings from this research are expected to provide valuable insights into the potential benefits of TAP block on gastrointestinal motility and overall recovery after bariatric surgery.",[62,29],"Obesity",[64,65,66,67],"TAP Block","Gastrointestinal Motility","PRO-diGI Scale","Sleeve Gastrectomy","2025-09-09",{"date":70,"type":39},"2025-09-11",{"date":72,"type":22},"2025-09-01",{"date":74,"type":22},"2025-11-30",{"name":76,"class":46},"Elazıg Fethi Sekin Sehir Hastanesi",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100576230","phase-2-a-phase--study-of-mosapride-citrate-injection-in-the-treatment-of-postoperative-gastrointestinal-dysfunction-100576230","NCT06782594","A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction","A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction","Inclusion Criteria:\n\n1）Voluntary participation and signing of informed consent;\n\n2\\) Aged ≥18 years and ≤75 years and BMI≤28kg\u002Fm2, regardless of gender;\n\n3\\) Patients undergoing elective laparoscopic-assisted intestinal resection and the surgical site is part of the intestinal segment from the ileocecal region to the sigmoid colon;\n\n4\\) Vital organ functions meet the following requirements:iver function:\n\nALT and AST≤3×ULN, total bilirubin level≤2×ULN;\n\nRenal function: serum creatinine (Cr)≤1.5×ULN or creatinine clearance≥50mL\u002Fmin (when Cr\\>1.5×ULN);\n\nBlood routine examination: hemoglobin (HGB)≥80g\u002FL;\n\nBlood biochemistry: albumin (ALB)≥30g\u002FL;\n\n5\\) Those classified as physical condition 1 to 3 by the American Society of Anesthesiologists (ASA).\n\nExclusion Criteria:\n\n1\\) Patients with a history of clinically significant drug allergy or known allergy to the study drug ingredients and excipients;\n\n2）Those who have a history of severe heart, lung, liver, kidney, blood, endocrine, immune, skin, neurological or mental diseases in the past two years or currently have diseases of the above systems;\n\n3\\) Those with a history of drug abuse in the past 6 months;\n\n4\\) Those with a history of constipation in the past 6 months (less than 3 bowel movements per week);\n\n5\\) Severe mechanical intestinal obstruction that is not expected to be relieved after surgery, short bowel syndrome, significant gastrointestinal motility disorders (such as gastroparesis, scleroderma, chronic intestinal pseudo-obstruction), poorly controlled Those with diabetes (HbA1c\\>8.5%) or gastrointestinal pacemakers installed in their bodies;\n\n6\\) Patients with inflammatory bowel disease (ulcerative colitis or Crohn's disease) and intestinal adhesions;\n\n7\\) Those who have undergone major abdominal surgery (such as gastrectomy, gastric bypass, sleeve gastrectomy, gastric band surgery, Whipple surgery, pancreatectomy, colectomy, hemicolectomy);\n\n8\\) QTcF interval: ≥450 milliseconds for men and ≥470 milliseconds for women (the QT interval must be corrected for heart rate using the Fridericia formula \\[QTcF\\]);\n\n9\\) Patients who received chemotherapy within 4 weeks before surgery;\n\n10\\) Those who are scheduled for emergency surgery or undergo any of the following surgeries: appendectomy, low anterior resection, colostomy, ileostomy, or stoma reversal, or diagnosed with needing proctocolectomy\u002Flow anterior resection Subjects whose disease may cause impaired rectal function or postoperative incontinence (except for lesions that do not involve the sigmoid colon and above);\n\n11\\) Within 3 days before the first dose, patients had received stimulants such as alvimopan, erythromycin, prucalopride, metoclopramide, domperidone, cisapride, mosapride, renzapride or azithromycin. Gastrointestinal motility drugs;\n\n12\\) Pregnant or lactating women, as well as those who plan to become pregnant or donate sperm or eggs during the study period and within 3 months after the end of the study, and are unwilling to use a medically recognized contraceptive measure (such as intrauterine contraceptive device or contraceptive) during the study period. sets);\n\n13\\) Participated in other clinical trials within 3 months before enrollment;\n\n14\\) Other subjects deemed unsuitable for inclusion by the researcher.","75 Years",{"count":21,"type":22},[87],"PHASE2","This study is a multicenter, randomized, double-blind, parallel, placebo-controlled phase II clinical study.",[29],"RECRUITING","2025-01-16",{"date":93,"type":39},"2025-01-20",{"date":95,"type":39},"2024-10-18",{"date":97,"type":22},"2025-10",{"name":99,"class":100},"Shandong New Time Pharmaceutical Co., LTD","INDUSTRY",2]